gdc

Newsworthy

Calquence Newest Treatment Approved for Mantle-Cell Lymphoma
FDA NewsLymphomaNewsworthy
In October 2017, the FDA accelerated the approval of Calquence for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy.
Verzenio a New Targeted Therapy Approved for Metastatic Breast Cancer
Breast CancerFDA NewsNewsworthy
Read about Verzenio, which was approved by the FDA in 2017, in combination with fulvestrant, for treatment of women with HR-positive, HER2-positive, HER2-negative advanced, or metastatic breast cancer that progressed after endocrine therapy.
Lynparza Approved as Maintenance Treatment for Ovarian Cancer
FDA NewsNewsworthyOvarian Cancer
In August 2017, the FDA approved Lynparza tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a response to platinum-based chemotherapy.
Neratinib First Long-Term Adjuvant Therapy for Early-Stage, HER2-Positive Breast Cancer
Breast CancerFDA NewsNewsworthy
On July 17, 2017, the FDA approved Nerlynx (neratinib; from Puma Biotechnology) for long-term adjuvant treatment of early-stage, HER2-positive breast cancer in patients who received previous therapy with Herceptin (trastuzumab).
Gene Therapy a New Milestone in Immunotherapy
ImmunotherapyNewsworthy
CAR T-cell therapy is a new type of immunotherapy that uses the patient’s genetically modified immune T-cells to attack cancer cells. In 2017, the FDA approved the first 2 CAR T-cell therapies for several types of blood cancer.
Page 3 of 5
Results 21 - 30 of 50

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country